Sarah Jessica Parker cuts ties with EpiPen

Joining scores of people outraged over the price hike of the EpiPen, Sarah Jessica Parker will no longer be associated with the drugmaker who manufactures it.

The actress cut ties with pharmaceutical giant Mylan N.V., which makes the emergency allergy treatment, in a statement Thursday.

Reports surfaced this week that the price of the EpiPen twin pack climbed to $608 earlier this year, according to the Associated Press. Contrast that to 2007, when an EpiPen cost $57.

“I’m left disappointed, saddened and deeply concerned by Mylan’s actions,” said Parker in an Instagram post. “I do not condone this decision and I have ended my relationship with Mylan as a direct result of it.”

Parker's 13-year-old son James has severe peanut and hazelnut allergies, and she was was previously part of a campaign with Mylan.

“I hope they will seriously reconsider the outpouring of voices of those millions of people who are dependent on the device, and take swift action to lower the cost to be more affordable for whom it is a life-saving necessity," she wrote.

In response to the firestorm, the drugmaker announced Thursday it would offer discounts for the EpiPen, including coupons covering up to $300 "for patients in health plans who face higher out-of-pocket costs."

EpiPen maker to offer discounts after price hike firestorm

Mylan also said it would double the income level at which families are eligible for assistance in purchasing the medication to four times the federal poverty level, which is $24,300 for a family of four. The company said a family of four with income up to $97,200 won't pay out of pocket.

Almost immediately, critics assailed Mylan's discount announcement, saying the list price isn't changing and that ultimately consumers will bear most of the costs.

Ex-pharma CEO Martin Shkreli defends EpiPen price increase

Contributing: The Associated Press, Nathan Bomey